In vitro evaluation of current and novel antivirals in combination against human cytomegalovirus

Human cytomegalovirus (HCMV) can cause severe disease in patients with compromised or immature immune systems. Currently approved pharmacotherapies for the treatment of systemic HCMV infections [ganciclovir (GCV), cidofovir (CDV), foscarnet] are limited by a high incidence of adverse effects and/or...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Antiviral research 2018-10, Vol.158, p.255-263
Hauptverfasser:	O’Brien, M. Shea, Markovich, Kylie C., Selleseth, Dean, DeVita, Alexa V., Sethna, Phiroze, Gentry, Brian G.
Format:	Artikel
Sprache:	eng
Schlagworte:	Antiviral Agents - administration & dosage Antiviral Agents - pharmacology Antiviral Agents - therapeutic use BDCRB Benzimidazoles - pharmacology Brincidofovir Cell Line Cidofovir - pharmacology Combination therapy Cyclopropanes - pharmacology Cyclopropavir Cytomegalovirus - drug effects Cytomegalovirus Infections - drug therapy Cytosine - analogs & derivatives Cytosine - pharmacology DNA-Directed DNA Polymerase - drug effects Drug Antagonism Drug Combinations Drug Resistance, Viral - drug effects Drug Resistance, Viral - genetics Drug Synergism Drug Therapy, Combination Endodeoxyribonucleases - antagonists & inhibitors Fibroblasts Foscarnet - pharmacology Ganciclovir - pharmacology Guanine - analogs & derivatives Guanine - pharmacology Human cytomegalovirus Humans Letermovir Maribavir Nucleic Acid Synthesis Inhibitors - pharmacology Organophosphonates - pharmacology Ribonucleosides - pharmacology Viral Proteins - antagonists & inhibitors Virus Replication - drug effects
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!